GlassScriptPhysician profile
Matthew Lambiase
NPI 1679548440
$33,515.46
in general payments reported to CMS, 2019-2025
28 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $503 · 2021: $876 · 2022: $3,830 · 2023: $5,400 · 2024: $1,385 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,655 · Food and Beverage: $3,732 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,654.83 |
| Food and Beverage | $3,731.65 |
| Education | $203.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $26,536.90 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Abbvie INC. | $1,989.78 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $556.78 | 2022-2025 | Ilumya |
| Janssen Biotech, INC. | $526.26 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $425.92 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $360.97 | 2020-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $336.23 | 2023-2025 | Zoryve |
| Incyte Corporation | $298.20 | 2020-2025 | Opzelura |
| Allergan, INC. | $287.94 | 2019-2022 | |
| Almirall LLC | $268.97 | 2019-2024 | Seysara |
| Ucb, INC. | $264.36 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $263.20 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $194.77 | 2019-2025 | |
| Genzyme Corporation | $178.55 | 2021-2024 | |
| Pfizer INC. | $145.50 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $144.32 | 2024-2025 | Daxxify |
| Merz North America, INC. | $133.20 | 2024-2025 | |
| Organon LLC | $132.81 | 2025 | Vtama, Nexplanon |
| Celgene Corporation | $90.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.80 | 2024-2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $85.31 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $52.21 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $40.12 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.01 | 2022 | |
| Botanix Sb INC | $25.95 | 2025 | Sofdra |
| Mimedx Group, INC. | $25.53 | 2025 | |
| Dermira, INC. | $15.52 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lambiase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.